|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,914.75 GBX | -0.56% |
|
-2.09% | +5.07% |
| 06-19 | FTSE 100 flat as investors weigh US-Iran peace talks, energy stocks support | RE |
| 06-18 | Moderna Secures Favorable FDA Panel Recommendation for mRNA Flu Vaccine |  |
Company Valuation: GSK plc
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 80,458 | 58,381 | 59,112 | 54,944 | 73,201 | 76,724 | - | - |
| Change | - | -27.44% | 1.25% | -7.05% | 33.23% | 4.81% | - | - |
| Enterprise Value (EV) 1 | 100,296 | 75,578 | 74,152 | 68,039 | 87,654 | 90,977 | 87,914 | 85,569 |
| Change | - | -24.65% | -1.89% | -8.24% | 28.83% | 3.79% | -3.37% | -2.67% |
| P/E | 18.6x | 3.93x | 11.9x | 21.3x | 12.9x | 12.4x | 11.4x | 11.2x |
| PBR | 5.34x | 5.47x | 4.4x | 4.02x | - | 4.46x | 3.71x | 3.2x |
| PEG | - | 0x | -0.2x | -0.4x | 0x | 1.2x | 1.43x | 4.33x |
| Capitalization / Revenue | 2.36x | 1.99x | 1.95x | 1.75x | 2.24x | 2.27x | 2.16x | 2.1x |
| EV / Revenue | 2.94x | 2.58x | 2.45x | 2.17x | 2.68x | 2.69x | 2.48x | 2.34x |
| EV / EBITDA | 8.85x | 7.23x | 6.37x | 6.36x | 7.77x | 7.92x | 7.16x | 6.83x |
| EV / EBIT | 11.4x | 9.27x | 8.44x | 7.44x | 8.96x | 8.94x | 8.02x | 7.48x |
| EV / FCF | 22.6x | 12.1x | 13.6x | 13x | 13.7x | 16.3x | 14.6x | 13.6x |
| FCF Yield | 4.42% | 8.28% | 7.36% | 7.67% | 7.32% | 6.15% | 6.87% | 7.37% |
| Dividend per Share 2 | 1 | 0.6125 | 0.58 | 0.61 | 0.66 | 0.7006 | 0.7328 | 0.763 |
| Rate of return | 4.98% | 4.26% | 4% | 4.53% | 3.62% | 3.64% | 3.81% | 3.96% |
| EPS 2 | 1.082 | 3.662 | 1.216 | 0.632 | 1.411 | 1.558 | 1.682 | 1.725 |
| Distribution rate | 92.4% | 16.7% | 47.7% | 96.5% | 46.8% | 45% | 43.6% | 44.2% |
| Net sales 1 | 34,114 | 29,324 | 30,328 | 31,376 | 32,667 | 33,794 | 35,477 | 36,579 |
| EBITDA 1 | 11,330 | 10,449 | 11,635 | 10,693 | 11,278 | 11,481 | 12,281 | 12,525 |
| EBIT 1 | 8,806 | 8,151 | 8,786 | 9,148 | 9,783 | 10,181 | 10,967 | 11,432 |
| Net income 1 | 4,385 | 14,956 | 4,928 | 2,575 | 5,716 | 6,266 | 6,669 | 6,902 |
| Net Debt 1 | 19,838 | 17,197 | 15,040 | 13,095 | 14,453 | 14,252 | 11,189 | 8,844 |
| Reference price 2 | 20.08 | 14.38 | 14.50 | 13.46 | 18.24 | 19.26 | 19.26 | 19.26 |
| Nbr of stocks (in thousands) | 4,006,383 | 4,060,999 | 4,076,145 | 4,080,519 | 4,012,126 | 3,984,652 | - | - |
| Announcement Date | 2/9/22 | 2/1/23 | 1/31/24 | 2/5/25 | 2/4/26 | - | - | - |
1GBP in Million2GBP
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 12.36x | 2.69x | 7.92x | 3.64% | 101B | |
| 32.01x | 11.69x | 23.99x | 0.62% | 980B | |
| 24.41x | 5.63x | 15.32x | 2.34% | 550B | |
| 26.86x | 6.49x | 13.28x | 3.17% | 382B | |
| 17.04x | 4.24x | 10.43x | 3.13% | 316B | |
| 21.94x | 4.59x | 13.02x | 1.91% | 272B | |
| 20.28x | 5.27x | 12.78x | 3.05% | 268B | |
| 13x | 4.83x | 9.94x | 3.87% | 199B | |
| 21.95x | 5.91x | 10.33x | 2.99% | 182B | |
| -44.34x | 5.36x | 29.54x | 2.62% | 154B | |
| Average | 14.55x | 5.67x | 14.65x | 2.73% | 340.38B | |
| Weighted average by Cap. | 21.40x | 7.10x | 16.59x | 2.21% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- GSK Stock
- Valuation GSK plc
Select your edition
All financial news and data tailored to specific country editions
